ZA200202270B - Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines. - Google Patents
Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines. Download PDFInfo
- Publication number
- ZA200202270B ZA200202270B ZA200202270A ZA200202270A ZA200202270B ZA 200202270 B ZA200202270 B ZA 200202270B ZA 200202270 A ZA200202270 A ZA 200202270A ZA 200202270 A ZA200202270 A ZA 200202270A ZA 200202270 B ZA200202270 B ZA 200202270B
- Authority
- ZA
- South Africa
- Prior art keywords
- vaccine
- antigen
- virus
- influenza
- polyoxyethylene sorbitan
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 92
- 239000002671 adjuvant Substances 0.000 title claims description 39
- 229920002113 octoxynol Polymers 0.000 title claims description 19
- 229940066429 octoxynol Drugs 0.000 title claims description 17
- -1 sorbitan ester Chemical class 0.000 title description 7
- 102000036639 antigens Human genes 0.000 claims description 84
- 108091007433 antigens Proteins 0.000 claims description 84
- 239000000427 antigen Substances 0.000 claims description 83
- 239000000203 mixture Substances 0.000 claims description 54
- 229920000136 polysorbate Polymers 0.000 claims description 24
- 241000700605 Viruses Species 0.000 claims description 22
- 241000712461 unidentified influenza virus Species 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 19
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 19
- 206010022000 influenza Diseases 0.000 claims description 18
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 17
- 229920000053 polysorbate 80 Polymers 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 230000000890 antigenic effect Effects 0.000 claims description 11
- 239000007921 spray Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 229920002114 octoxynol-9 Polymers 0.000 claims description 7
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 6
- 239000003833 bile salt Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 208000002672 hepatitis B Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 238000012737 microarray-based gene expression Methods 0.000 claims description 4
- 210000004877 mucosa Anatomy 0.000 claims description 4
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 241000701806 Human papillomavirus Species 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 241000588653 Neisseria Species 0.000 claims description 3
- 241000224016 Plasmodium Species 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 2
- 241000588807 Bordetella Species 0.000 claims description 2
- 241000589968 Borrelia Species 0.000 claims description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 2
- 241000606161 Chlamydia Species 0.000 claims description 2
- 241000606790 Haemophilus Species 0.000 claims description 2
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 2
- 208000016604 Lyme disease Diseases 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 108010008707 Mucin-1 Proteins 0.000 claims description 2
- 102000036673 PRAME Human genes 0.000 claims description 2
- 108060006580 PRAME Proteins 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 241000223996 Toxoplasma Species 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims 5
- 241000725619 Dengue virus Species 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 229940124873 Influenza virus vaccine Drugs 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 241000204031 Mycoplasma Species 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 201000010284 hepatitis E Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 40
- 229960003971 influenza vaccine Drugs 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 230000028993 immune response Effects 0.000 description 14
- 229920004890 Triton X-100 Polymers 0.000 description 13
- 239000013504 Triton X-100 Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 10
- 102000037865 fusion proteins Human genes 0.000 description 10
- 239000002736 nonionic surfactant Substances 0.000 description 10
- 230000005847 immunogenicity Effects 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 230000009885 systemic effect Effects 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 9
- 108700006640 OspA Proteins 0.000 description 8
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 7
- 101710188053 Protein D Proteins 0.000 description 7
- 101710132893 Resolvase Proteins 0.000 description 7
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 7
- 229960003964 deoxycholic acid Drugs 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000002850 nasal mucosa Anatomy 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 108700023315 OspC Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 101100431670 Rattus norvegicus Ybx3 gene Proteins 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 230000035931 haemagglutination Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 3
- 229960001212 bacterial vaccine Drugs 0.000 description 3
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 239000002812 cholic acid derivative Substances 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229960004906 thiomersal Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 108030001720 Bontoxilysin Proteins 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 208000000907 Condylomata Acuminata Diseases 0.000 description 2
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000701828 Human papillomavirus type 11 Species 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 101710105759 Major outer membrane porin Proteins 0.000 description 2
- 101710164702 Major outer membrane protein Proteins 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- 241000588655 Moraxella catarrhalis Species 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 102100035181 Plastin-1 Human genes 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940053031 botulinum toxin Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 102000022382 heparin binding proteins Human genes 0.000 description 2
- 108091012216 heparin binding proteins Proteins 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 229940124735 malaria vaccine Drugs 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 108010049148 plastin Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- PMTMAFAPLCGXGK-JMTMCXQRSA-N (15Z)-12-oxophyto-10,15-dienoic acid Chemical compound CC\C=C/C[C@H]1[C@@H](CCCCCCCC(O)=O)C=CC1=O PMTMAFAPLCGXGK-JMTMCXQRSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 101100162403 Arabidopsis thaliana ALEU gene Proteins 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 241000588780 Bordetella parapertussis Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000589978 Borrelia hermsii Species 0.000 description 1
- 241000495356 Borrelia microti Species 0.000 description 1
- 241000589972 Borrelia sp. Species 0.000 description 1
- 241001148604 Borreliella afzelii Species 0.000 description 1
- 241000142472 Borreliella andersonii Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241001148605 Borreliella garinii Species 0.000 description 1
- 241000589893 Brachyspira hyodysenteriae Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589877 Campylobacter coli Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 102100031262 Deleted in malignant brain tumors 1 protein Human genes 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 241000605314 Ehrlichia Species 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 241001133638 Entamoeba equi Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 101100406392 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) omp26 gene Proteins 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000844721 Homo sapiens Deleted in malignant brain tumors 1 protein Proteins 0.000 description 1
- 101001130441 Homo sapiens Ras-related protein Rap-2a Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010071038 Human anaplasmosis Diseases 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 description 1
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000589929 Leptospira interrogans Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 241000588622 Moraxella bovis Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- HCUVEUVIUAJXRB-UHFFFAOYSA-N OC1=C(C=C(CNC(CCCC=2SC=CC=2)=O)C=C1)OC Chemical compound OC1=C(C=C(CNC(CCCC=2SC=CC=2)=O)C=C1)OC HCUVEUVIUAJXRB-UHFFFAOYSA-N 0.000 description 1
- PMTMAFAPLCGXGK-UHFFFAOYSA-N OPDA Natural products CCC=CCC1C(CCCCCCCC(O)=O)C=CC1=O PMTMAFAPLCGXGK-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101100028078 Oryza sativa subsp. japonica OPR1 gene Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 101710099976 Photosystem I P700 chlorophyll a apoprotein A1 Proteins 0.000 description 1
- 101000983333 Plasmodium falciparum (isolate NF54) 25 kDa ookinete surface antigen Proteins 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 101710183389 Pneumolysin Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 102100022851 Rab5 GDP/GTP exchange factor Human genes 0.000 description 1
- 102100031420 Ras-related protein Rap-2a Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 101710203837 Replication-associated protein Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000606695 Rickettsia rickettsii Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 101000999689 Saimiriine herpesvirus 2 (strain 11) Transcriptional regulator ICP22 homolog Proteins 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 108010011834 Streptolysins Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 101710137302 Surface antigen S Proteins 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 101710134694 Transcriptional regulator ICP22 homolog Proteins 0.000 description 1
- 102000010912 Transferrin-Binding Proteins Human genes 0.000 description 1
- 108010062476 Transferrin-Binding Proteins Proteins 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 229920004892 Triton X-102 Polymers 0.000 description 1
- 229920004893 Triton X-165 Polymers 0.000 description 1
- 229920004894 Triton X-305 Polymers 0.000 description 1
- 229920004897 Triton X-45 Polymers 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 241000606834 [Haemophilus] ducreyi Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 101150078331 ama-1 gene Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 108091016312 choline binding proteins Proteins 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 231100000249 enterotoxic Toxicity 0.000 description 1
- 230000002242 enterotoxic effect Effects 0.000 description 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 201000009163 human granulocytic anaplasmosis Diseases 0.000 description 1
- 208000022340 human granulocytic ehrlichiosis Diseases 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002130 immunocastration Effects 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 201000003866 lung sarcoma Diseases 0.000 description 1
- 101710130522 mRNA export factor Proteins 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 229940099789 ospa protein Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 108010021711 pertactin Proteins 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940045946 sodium taurodeoxycholate Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940031418 trivalent vaccine Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 239000000522 vaginal cream Substances 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Description
oN
Vaccines & * - The present invention relates to a novel adjuvant system comprising a polyoxyethylene sorbitan ester surfactant in combination with an octoxynol. The . present invention provides said novel adjuvants, vaccines comprising them, and methods for their manufacture and for their formulation into vaccines. The use of the . adjuvants or vaccines of the present invention in the prophylaxis or therapy of disease is also provided. The adjuvants are particularly useful as mucosal adjuvants, but are also effective systemically. The adjuvants are especially useful in the context of influenza vaccines.
Apart from bypassing the requirement for painful injections and the associated negative affect on patient compliance because of “needle fear”, mucosal vaccination is attractive since it has been shown in animals that mucosal administration of antigens has a greater efficiency in inducing protective responses at mucosal surfaces, which is the route of entry of many pathogens. In addition, it has been suggested that mucosal vaccination, such as intranasal vaccination, may induce mucosal immunity not only in the nasal mucosa, but also in distant mucosal sites such as the genital mucosa (Mestecky, 1987, Journal of Clinical Immunology, 7, 265-276; McGhee and
Kiyono, Infectious Agents and Disease, 1993, 2, 55-73). Despite much research in the field, safe and effective adjuvants which are suitable for use in humans, remain to be identified. The present invention provides a solution to this problem.
Medical uses of certain non-ionic surfactants have been described. For example, intranasal administration of polyoxyethylene sorbitan esters, polyoxyethylene ethers, bile salts, and other permeation enhancers, for the enhancement of insulin uptake in the nasal cavity has been described (Hirai ef al. 1981, International Journal of
Pharmaceutics, 9, 165-172; Hirai ef al. 1981, International Journal of Pharmaceutics, 9, 173-184).
Other non-ionic surfactant formulations have been utilised. For example, vaccine preparations comprising an admixture of either polyoxyethylene castor oil or caprylic/capric acid glycerides, with polyoxyethylene sorbitan monoesters, and an antigen, are capable of inducing systemic immune responses after topical r ® administration to a mucosal membrane (WO 94/17827). This patent application discloses the combination of the non-ionic surfactant TWEEN20™ (polyoxyethylene sorbitan monoester) and Imwitor742™ (caprylic/capric acid glycerides), or a combination of TWEEN20™ and polyoxyethylene castor oil is able to enhance the systemic immune response following intranasal immunisation. Details of the effect of this formulation on the enhancement of the immune response towards intranasally administered antigens have also been described in the literature (Gizurarson ef al. 1996. Vaccine Research, 5, 69-75; Aggerbeck et al. 1997, Vaccine, 15, 307-316;
Tebbey et al.,Viral Immunol 1999;12(1):41-5). In the examples shown in WO 94/17827, (in particular example 4) the concentration of TWEEN20™ that is required to enhance the immune response is very high (36%), whereas at 28% even in the presence of the caprylic/capric acid glyceride no enhancement of the immune response occurs.
Non-ionic surfactants have also been formulated in such a way as to form non-ionic surfactant vesicles (commonly known as NISV; US 5,679,355). Such formulations of non-ionic surfactants, often in the presence of cholesterol, form lipid-bilayer vesicles which entrap antigen within the inner aqueous phase or within the bilayer itself.
WO 96/36352 and US 5,653,987 describe a liquid pharmaceutical agent comprising at least two absorption enhancers and water, primarily for oral insulin delivery, wherein the amount of each absorption enhancing agent is present in a concentration of from 1 to 10 % w/w of the total formulation.
Surfactants are commonly used in the formulation of oil emulsion adjuvants for systemic administration, and function to stabilise the oil droplets. For example, polyoxyethylene sorbitan esters (TWEENT™) and sorbitan fatty acid esters (SPANTM) are used to stabilise oil in water emulsions (EP 0 399 843, WO 95/17210).
Influenza virus vaccines have been prepared in the past by the use of Triton X-100 or a mixture of Tween and ether to split influenza virus. A clinical comparison of the systemic immunogenicity of the two splits shows that they are comparable (Gross et al. 1981. J. Clin Microbiol 14, 534-8). Other surfactants have also been investigated for their effect on the immunogenicity of the resulting split vaccine. In a comparative
CL ¢ 4 study of parenteral administration Mukhlis et al. (1984 Vaccine 2, 199-203) showed that whole virus was more immunogenic than detergent disrupted virus, but that between different detergents Triton X-100 and cetyl trimethyl ammonium bromide (CTAB) gave marginally more immunogenic splits than the detergent empigen.
The applicant presents here the surprising finding that polyoxyethylene sorbitan esters in combination with an octoxynol together act as a potent adjuvant for vaccines.
Advantageously, such compositions may be administered systemically, but are sufficient to induce systemic immune responses when administered mucosally. The immune responses induced by mucosal administration of vaccines of the present invention may be at least as high as or at least comparable to those observed after a systemic injection of conventional vaccine.
The present invention provides safe and potent adjuvants which are easy to manufacture, which may be administered either through mucosal or systemic routes.
In a first aspect the invention provides an adjuvant which comprises a polyoxyethylene sorbitan ester and an octoxynol.
In another aspect the invention provides a vaccine comprising an adjuvant according to the invention, together with an antigen.
Particularly preferred is a vaccine composition comprising an adjuvant according to - the inventisn together with influenza virus antigen for administration to a mucssal Cee ee surface, in particularly to the nasal mucosa. However, there are alternative routes of administration and other possible antigens for use in a vaccine according to the invention which will be described below.
Octoxynols and polyoxyethylene sorbitan esters are described in “Surfactant systems”
Eds: Attwood and Florence (1983, Chapman and Hall). The octoxynol series, including t-octylphenoxypolyethoxyethanol (TRITON X-100TM) is also described in
Merck Index Entry 6858 (Page 1162, 12™ Edition, Merck & Co. Inc., Whitehouse
Station, N.J., USA; ISBN 0911910-12-3). The polyoxyethylene sorbitan esters, including polyoxyethylene sorbitan monooleate (TWEENSOTM) are described in
» a
Merck Index Entry 7742 (Page 1308, 12" Edition, Merck & Co. Inc., Whitehouse
Station, N.J., USA; ISBN 0911910-12-3). Both may be manufactured using methods described therein, or purchased from commercial sources such as Sigma Inc.
Preferred octoxynols for use in the adjuvants according to the invention include other non-ionic surfactants from the Triton series, such as Triton X-45, Triton X-102, . + Tnton X-114, Triton X-165, Triton X-205, Triton X-305, Triton N-57, Triton N-101 and Triton N-128, but t-octylphenoxypolyethoxyethanol (Triton X-100) is particularly preferred.
The adjuvants of the present invention comprise a polyoxyethylene sorbitan esterand an octoxynol. Preferably the octoxynol is t-octylphenoxypolyethoxyethanol (TRITON -X-100™), Preferably the polyoxyethylene sorbitan ester is polyoxyethylene sorbitan monooleate (TWEENS80™),
The adjuvant according to the invention may advantageously further comprise a bile salt or a cholic acid derivative.
Accordingly the adjuvant may comprise a polyoxyethylene sorbitan ester such as : polyoxyethylene sorbitan monooleate (Tween 80), an octoxynol such as t- octylphenoxy polyethoxyethanol (Triton X-100) and a bile salt or cholic acid derivative such as sodium deoxycholate or taurodeoxycholate. In a preferred embodiment, the invention provides an adjuvant formulation comprising polyoxyethylene sorbitan monooleate (Tween 80), t-octylphenoxy polyethoxyethanol (Triton X-100) and sodium deoxycholate.
Preferably, the total concentration of non-ionic surfactants present in the adjuvant formulation is less than 40%, more preferably up to about 20%. A preferred range is between about 0.001% to 20%, more preferably 0.01 to 10% and most preferably up to about 2% (w/v).
The individual non-ionic surfactants have preferred concentrations in the final vaccine composition as follows: octyl-or nonylphenoxy polyethoxyethanols such as Triton X- 100 or other detergents in the Triton series: from 0.001% to 20%, preferably 0.001%
‘to 10%, more preferably from 0.001 to 1% and most preferably 0.005 to 0.1% (Wh; ¢ ‘polyoxyethylene sorbitan esters such as Tween 80: 0.01 to 1%, most preferably about 0.0% (w/v). ; Particularly prefered ranges for the concentrations of the non-ionic surfactants are:
Tween 80™: 0.01 to 1%, most preferably about 0.1% (v/v);
Triton X-100™: 0.001 to 0.1, most preferably 0.005 to 0.02 % (w/v).
One aspect of the present invention is a vaccine formulation comprising a polyoxyethylene sorbitan ester surfactant in combination with an octoxynol, wherein the antigen present in the vaccine is not entrapped within a non-ionic surfactant vesicle.
Influenza virus antigens for use in the vaccine according to the invention may be any form of influenza antigens suitable for raising an immune response, including live or inactivated whole virus, split virus, or subunit antigens prepared from whole virus or by recombinant means. Influenza virus for production of the antigen may be grown in embryonated eggs in a conventional process or the virus may be grown in tissue culture. Suitable cell substrates for tissue culture of influenza include for example dog kidney cells such as MDCK cells, cells from a clone of MDCK, or MDCK -like cells, monkey kidney cells such as AGMK cells including Vero cells, or any other cell type suitable for the production of influenza virus for vaccine purposes. Suitable cell E substrates also include human cells e.g. MRC-5 cells. Suitable cell substrates are not limited to cell lines; for example primary cells such as chicken embryo fibroblasts arc Cea also included.
Preferred is an influenza virus antigen preparation which comprises split virus which has undergone a series of purification steps. Thus the antigen preparation may be produced by a number of different commercially applicable processes, for example the split flu process described in patent no. DD 300 833 and DD 211 444, incorporated herein by reference. Commercially available split influenza vaccine includes Fluarix™ which is sold by SmithKline Beecham.
" * Accordingly a preferred vaccine formulation according to the invention comprises egg or tissue culture derived influenza antigen, preferably split influenza antigen, together with a polyoxyethylene sorbitan ester and an octoxynol, optionally further comprising a bile salt or derivative of cholic acid. Most preferably such a formulation comprises split influenza virus antigen, polyoxyethylene sorbitan monooleate (Tween 80), t- octylphenoxypolyethoxyethanol (Triton X-100) and sodium deoxycholate.
The influenza vaccine according to the invention is preferably a multivalent influenza vaccine comprising two or more strains of influenza. Most preferably it is a trivalent vaccine comprising three strains. Conventional influenza vaccines comprise three strains of influenza, two A strains and one B strain. However, monovalent vaccines, which may be useful for example in a pandemic situation, are not excluded from the invention. A monovalent, pandemic flu vaccine will most likely contain influenza antigen from a single A strain. : : + The vaccine preparations of the present invention are preferably used to protect or . treat a mammal susceptible to, or suffering from disease, by means of administering : said vaccine via a mucosal route, such as the oral/bucal/intestinal/vaginal/rectal or - nasal route. Such administration may be in a droplet, spray, or dry powdered form.
Nebulised or aerosolised vaccine formulations also form part of this invention.
Enteric formulations such as gastro resistant capsules and granules for oral : administration, suppositories for rectal or vaginal administration also form part of this invention. The present invention may also be used to enhance the immunogenicity of . antigens applied to the skin (transdermal or transcutaneous delivery). In addition, the adjuvants of the present invention may be parentally delivered, for example intramuscular, or subcutaneous administration. When used for intranasal vaccination, the vaccines of the present invention are preferably haemolytic in nature.
Depending on the route of administration, a variety of administration devices may be used. For example, for the preferred, intranasal route of administration, a spray device such as the commercially available Accuspray™ (Becton Dickinson) may be used.
. ¢
Preferred spray devices for intranasal use are devices for which the performance of the device is not dependent upon the pressure applied by the user. These devices are known as pressure threshold devices. Liquid is released from the nozzle only when a threshold pressure is attained. These devices make it easier to achieve a consistent spray witha regular droplet size. Pressure threshold devices suitable for use with the : present invention are known in the art and are described for example in WO 91/13281,EP 311 863 B and EP 516 636 B, incorporated herein by reference. Such devices are commercially available from Pfeiffer GmbH.
Preferred intranasal devices produce droplets (measured using water as the liquid) in the range | to 200pum, preferably 10 to 120pm. Below 10um there is a risk of inhalation, therefore it is desirable to have no more than about 5% of droplets below } 10um. Droplets above 120um do not spread as well as smaller droplets, so it is desirable to have no more than about 5% of droplets exceeding 120pum.
Bi-dose delivery is a further preferred feature of an intranasal delivery device for use with the vaccines according to the invention. Bi-dose devices contain two subdoses : of a single vaccine dose, one sub-dose for administration to each nostril. Generally the two sub-doses are in a single chamber and the construction of the device allows the efficient delivery of a single sub-dose at a time.
The invention provides in a further aspect a kit comprising an intranasal administration device as described herein containing a vaccine formulation according ] : to the invention. In a preferred embodiment of this aspect of the invention, the ST intranasal administration device is filled with an influenza vaccine.
For certain vaccine formulations, other vaccine components may be included in the formulation. As such the adjuvant formulations of the present invention may also comprise a bile acid or a derivative thereof, particular in the form of a salt. These include derivatives of cholic acid and salts thereof, in particular sodium salts of cholic acid or cholic acid derivatives. Examples of bile acids and derivatives thereof include cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, ursodeoxycholic acid, hyodeoxycholic acid and derivatives such as glyco-, tauro-,
vy 0) amidopropyl-1-propanesulfonic-, amidopropyl-2-hydroxy-1-propanesulfonic derivatives of the aforementioned bile acids, or N,N-bis (3Dgluconoamidopropyl) deoxycholamide. A particularly preferred example is sodium deoxycholate (NaDOC) which may be present in the final vaccine dose.
Preferably, the adjuvant formulations of the present invention are advantageous when in the form of an aqueous solution or a suspension of non-vesicular forms. Such formulations are easy to manufacture reproducibly, and also to sterilise (terminal filtration through a 450 or 220 nm pore membrane) and are easy to administer to the nasal mucosa in the form of a spray without degradation of the complex physical structure of the adjuvant.
In a further aspect of the present invention, there is provided a method of preparing a vaccine which method comprises admixing an adjuvant according to the invention with an antigen. : In a still further aspect, there is provided a method of inducing or enhancing an . immune response in a subject, comprising admixing the antigen and the adjuvant according to the invention, and administering said admixture to the subject.
Preferably, the route of administration to the subject is via a mucosal surface and more preferably via the nasal mucosa. When the vaccine is administered via the nasal mucosa, the vaccine is preferably administered as a spray. In a preferred method of : inducing or enhancing an immune response, a systemic response is induced by a nasal administration of the vaccine. Thus, a mucosal vaccine according to the invention is preferably capable of inducing a systemic immune response when administered via a mucosal route.
The present invention further provides the use of a polyoxyethylene sorbitan ester, and an octoxynol in the manufacture of an adjuvant formulation, in particular an adjuvant formulation for application to the mucosa of a patient. The present invention also relates to the use of a polyoxyethylene sorbitan ester, an octoxynol and an antigen, in the manufacture of a vaccine formulation, especially a vaccine formulation for application to the mucosa. Preferably the antigen is influenza virus antigen.
CJ
Particularly preferred are adjuvants and vaccines for administration to the nasal mucosa.
Preferably the administering of a vaccine according to the invention comprises the administration of a priming or a boosting dose of the vaccine, such as a priming or a boosting dose of influenza vaccine comprising an influenza antigen preparation.
It is foreseen that compositions of the present invention will be used to formulate vaccines containing antigens derived from a wide variety of sources. For example, antigens may include human, bacterial, or viral nucleic acid, pathogen derived antigen or antigenic preparations, tumour derived antigen or antigenic preparations, host- derived antigens, including GnRH and IgE peptides, recombinantly produced protein or peptides, and chimeric fusion proteins.
Preferably the vaccine formulations of the present invention contain an antigen or antigenic composition capable of eliciting an immune response against a human pathogen, which antigen or antigenic composition is derived from HIV-1, (such as tat, nef, gp120 or gp160), human herpes viruses, such as gD or derivatives thereof or
Immediate Early protein such as ICP27 from HSV1 or HSV2, cytomegalovirus ((esp
Human)(such as gB or derivatives thereof), Rotavirus (including live-attenuated viruses), Epstein Barr virus (such as gp350 or derivatives thereof), Varicella Zoster
Virus (such as gpl, II and IE63), or from a hepatitis virus such as hepatitis B virus (for example Hepatitis B Surface antigen or a derivative thereof), hepatitis A virus, os hepatitis C virus aid hepatitis E virus, ur from uthrer viral patitogens, such as CTT paramyxoviruses: Respiratory Syncytial virus (such as F and G proteins or derivatives thereof), parainfluenza virus, measles virus, mumps virus, human papilloma viruses (for example HPV, 11, 16, 18, ..), flaviviruses (e.g. Yellow Fever Virus, Dengue
Virus, Tick-borne encephalitis virus, Japanese Encephalitis Virus) or Influenza virus (whole live or inactivated virus, split influenza virus, grown in eggs or MDCK cells, or Vero cells or whole flu virosomes (as described by R. Gluck, Vaccine, 1992, 10, 915-920) or purified or recombinant proteins thereof, such as HA, NP, NA, or M proteins, or combinations thereof), or derived from bacterial pathogens such as
Neisseria spp, including N. gonorrhea and N. meningitidis (for example capsular polysaccharides and conjugates thereof, transferrin-binding proteins, lactoferrin
I binding proteins, PilC, adhesins); S. pyogenes (for example M proteins or fragments thereof, C5A protease, lipoteichoic acids), S. agalactiae, S. mutans; H. ducreyi;
Moraxella spp, including M catarrhalis, also known as Branhamella catarrhalis (for example high and low molecular weight adhesins and invasins); Bordetella spp, including B. pertussis (for example pertactin, pertussis toxin or derivatives thereof, filamenteous hemagglutinin, adenylate cyclase, fimbriae), B. parapertussis and B. bronchiseptica; Mycobacterium spp., including M. tuberculosis (for example ESATS,
Antigen 85A, -B or -C), M. bovis, M. leprae, M. avium, M. paratuberculosis, M. smegmatis; Legionella spp, including L. pneumophila; Escherichia spp, including enterotoxic E. coli (for example colonization factors, heat-labile toxin or derivatives thereof, heat-stable toxin or derivatives thereof), enterohemorragic E. coli, enteropathogenic E. coli (for example shiga toxin-like toxin or derivatives thereof);
Vibrio spp, including V. cholera (for example cholera toxin or derivatives thereof);
Shigella spp, including S. sonnei, S. dysenteriae, S. flexnerii; Yersinia spp, including
Y. enterocolitica (for example a Yop protein) , Y. pestis, Y. pseudotuberculosis; : Campylobacter spp, including C. jejuni (for example toxins, adhesins and invasins) : and C. coli; Salmonella spp, including S. typhi, S. paratyphi, S. choleraesuis, §. = enteritidis; Listeria spp., including L. monocytogenes, Helicobacter spp, including H. pylori (for example urease, catalase, vacuolating toxin); Pseudomonas spp, including
P. aeruginosa; Staphylococcus spp., including S. aureus, S. epidermidis;
Enterococcus spp., including E. faecalis, E. faecium; Clostridium spp., including C. : tetani (for example tetanus toxin and derivative thereof), C. botulinum (for example botulinum toxin and derivative thereof), C. difficile (for example clostridium toxins A : or B and derivatives thereof); Bacillus spp., including B. anthracis (for example botulinum toxin and derivatives thereof); Corynebacterium spp., including C. diphtheriae (for example diphtheria toxin and derivatives thereof); Borrelia spp., including B. burgdorferi (for example OspA, OspC, DbpA, DbpB), B. garinii (for example OspA, OspC, DbpA, DbpB), B. afzelii (for example OspA, OspC, DbpA,
DbpB), B. andersonii (for example OspA, OspC, DbpA, DbpB), B. hermsii; Ehrlichia spp., including E. equi and the agent of the Human Granulocytic Ehrlichiosis;
Rickettsia spp, including R. rickettsii; Chlamydia spp., including C. trachomatis (for example MOMP, heparin-binding proteins), C. pneumoniae (for example MOMP, heparin-binding proteins), C. psittaci, Leptospira spp., including L. interrogans;
Treponema spp., including T. pallidum (for example the rare outer membrane wv 4 proteins), T. denticola, T. hyodysenteriae; or derived from parasites such as
Plasmodium spp., including P. falciparum; Toxoplasma spp., including T. gondii (for example SAG2, SAG3, Tg34); Entamoeba spp., including E. histolytica; Babesia spp., including B. microti; Trypanosoma spp., including T. cruzi; Giardia spp., including
G. lamblia; Leshmania spp., including L. major; Pneumocystis spp., including P. carinii; Trichomonas spp., including T. vaginalis; Schisostoma spp., including S. mansoni, or derived from yeast such as Candida spp., including C. albicans;
Cryptococcus spp., including C. neoformans.
Preferred bacterial vaccines comprise antigens derived from Streptococcus spp, including S. pneumoniae (for example capsular polysaccharides and conjugates thereof, PsaA, PspA, streptolysin, choline-binding proteins) and the protein antigen
Pneumolysin (Biochem Biophys Acta, 1989, 67, 1007; Rubins et al., Microbial
Pathogenesis, 25, 337-342), and mutant detoxified derivatives thereof (WO 90/0695 1;
WO 99/03884). Other preferred bacterial vaccines comprise antigens derived from
Haemophilus spp., including H. influenzae type B (for example PRP and conjugates thereof), non typeable H. influenzae, for example OMP26, high molecular weight adhesins, PS, P6, protein D and lipoprotein D, and fimbrin and fimbrin derived peptides (US 5,843,464) or multiple copy varients or fusion proteins thereof, Other preferred bacterial vaccines comprise antigens derived from Moraxella Catarrhalis (including outer membrane vesicles thereof, and OMP106 (W097/41731)) and from
Neisseria mengitidis B (including outer membrane vesicles thereof), and NspA (WO ’ 96/29412).
Derivatives of Hepatitis B Surface antigen are well known in the art and include, inter alia, those PreS1, PreS2 S antigens set forth described in European Patent applications
EP-A-414 374; EP-A-0304 578, and EP 198-474. In one preferred aspect the vaccine formulation of the invention comprises the HIV-1 antigen, gp120, especially when expressed in CHO cells. In a further embodiment, the vaccine formulation of the invention comprises gD2t as hereinabove defined.
In a particular embodiment of the present invention vaccines containing the claimed adjuvant comprise antigen derived from the Human Papilloma Virus (HPV)
" "7 considered to be responsible for genital warts, (HPV 6 or HPV 11 and others), and the
HPV viruses responsible for cervical cancer (HPV 16, HPV18 and others).
Particularly preferred forms of genital wart prophylactic, or therapeutic, vaccine comprise L1 particles or capsomers, and fusion proteins comprising one or more antigens selected from the HPV 6 and HPV 11 proteins E6, E7, L1, and L2.
The most preferred forms of fusion protein are: L2E7 as disclosed in WO 96/26277, and protein D(1/3)-E7 disclosed in GB 9717953.5 (PCT/EP98/05285).
A preferred HPV cervical infection or cancer, prophylaxis or therapeutic vaccine composition may comprise HPV 16 or 18 antigens. For example, L1 or L2 antigen monomers, or L1 or L2 antigens presented together as a virus like particle (VLP) or the L1 alone protein presented alone in a VLP or capsomer structure. Such antigens, virus like particles and capsomer are per se known. See for example W094/00152, : WO094/20137, W0O94/05792, and W093/02184. 0 Additional early proteins may be included alone or as fusion proteins such as : preferably E7, E2 or ES for example; particularly preferred embodiments of this - includes a VLP comprising L1E7 fusion proteins (WO 96/11272). : Particularly preferred HPV 16 antigens comprise the early proteins E6 or E7 in fusion with a protein D carrier to form Protein D - E6 or E7 fusions from HPV 16, or combinations thereof; or combinations of E6 or E7 with L2 (WO 96/26277).
Alternatively the HPV 16 or 18 early proteins E6 and E7, may be presented in a single molecule, preferably a Protein D- E6/E7 fusion. Such vaccine may optionally contain either or both E6 and E7 proteins from HPV 18, preferably in the form of a Protein D - E6 or Protein D - E7 fusion protein or Protein D E6/E7 fusion protein.
The vaccine of the present invention may additionally comprise antigens from other
HPYV strains, preferably from strains HPV 6, 11, 31, 33, or 45.
Vaccines of the present invention may comprise antigens derived from parasites that ) cause Malaria. For example, preferred antigens from Plasmodia falciparum include
RTS,S and TRAP. RTS is a hybrid protein comprising substantially all the C-terminal portion of the circumsporozoite (CS) protein of P. falciparum linked via four amino acids of the preS2 portion of Hepatitis B surface antigen to the surface (S) antigen of hepatitis B virus. Its full structure is disclosed in the International Patent Application
No. PCT/EP92/02591, published under Number WO 93/10152 claiming priority from
UK patent application N0.9124390.7. When expressed in yeast RTS is produced as a lipoprotein particle, and when it is co-expressed with the S antigen from HBV it produces a mixed particle known as RTS,S. TRAP antigens are described in the
International Patent Application No. PCT/GB89/00895, published under WO 90/01496. A preferred embodiment of the present invention is a Malaria vaccine wherein the antigenic preparation comprises a combination of the RTS,S and TRAP antigens. Other plasmodia antigens that are likely candidates to be components of a multistage Malaria vaccine are P. faciparum MSP1, AMA1, MSP3, EBA, GLURP,
RAP1, RAP2, Sequestrin, PFEMP1, Pf332, LSA1, LSA3, STARP, SALSA, PfEXP1,
Pfs25, Pfs28, PFS27/25, Pfs16, Pfs48/45, Pfs230 and their analogues in Plasmodium spp.
The formulations may alternatively contain an anti-tumour antigen and be useful for the immunotherapeutic treatment of cancers. For example, the adjuvant formulation finds utility with tumour rejection antigens such as those for prostrate, breast, : colorectal, lung, pancreatic, renal or melanoma cancers. Exemplary antigens include oo. MAGE | and MAGE J or other MAGE antigens for the treatment of melanuia, a BE
PRAME, BAGE or GAGE (Robbins and Kawakami, 1996, Current Opinions in
Immunology 8, pps 628-636; Van den Eynde et al., International Journal of Clinical & -
Laboratory Research (submitted 1997); Correale et al. (1997), Journal of the National
Cancer Institute 89, p293. Indeed these antigens are expressed in a wide range of tumour types such as melanoma, lung carcinoma, sarcoma and bladder carcinoma.
Other Tumor-Specific antigens are suitable for use with adjuvant of the present invention and include, but are not restricted to Prostate specific antigen (PSA) or Her- 2/neu, KSA (GA733), MUC-1 and carcinoembryonic antigen (CEA). Accordingly in one aspect of the present invention there is provided a vaccine comprising an adjuvant composition according to the invention and a tumour rejection antigen.
w YF
Additionally said antigen may be a self peptide hormone such as whole length
Gonadotrophin hormone releasing hormone (GnRH, WO 95/20600), a short 10 amino acid long peptide, in the treatment of many cancers, or in immunocastration.
It is foreseen that compositions of the present invention will be used to formulate vaccines containing antigens derived from Borrelia sp.. For example, antigens may include nucleic acid, pathogen derived antigen or antigenic preparations, recombinantly produced protein or peptides, and chimeric fusion proteins. In particular the antigen is OspA. The OspA may be a full mature protein in a lipidated form virtue of the host cell (E.Coli) termed (Lipo-OspA) or a non-lipidated derivative.
Such non-lipidated derivatives include the non-lipidated NS1-OspA fusion protein which has the first 81 N-terminal amino acids of the non-structural protein (NS1) of the influenza virus, and the complete OspA protein, and another, MDP-OspA is a non-lipidated form of OspA carrying 3 additional N-terminal amino acids.
Vaccines of the present invention may be used for the prophylaxis or therapy of allergy. Such vaccines would comprise allergen specific (for example Der p1) and allergen non-specific antigens (for example peptides derived from human IgE, . including but not restricted to the stanworth decapeptide (EP 0 477 231 B1)). : The amount of protein in each vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical : vaccinees. Such amount will vary depending upon which specific immunogen is employed and how it is presented. Generally, it is expected that each dose will comprise 1-1000 pg of protein, preferably 1-500 pg, preferably 1-100ug, most preferably I to 50pg. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of appropriate immune responses in subjects. Following an initial vaccination, subjects may receive one or several booster immunisation adequately spaced.
The vaccines of the present invention may also be administered via the oral route. In such cases the pharmaceutically acceptable excipient may also include antacid
~ ¢ a buffers, or enteric capsules or microgranules. The vaccines of the present invention may also be administered by the vaginal route. In such cases, the pharmaceutically acceptable excipients may also include emulsifiers, polymers such as CARBOPOL®, and other known stablilisers of vaginal creams and suppositories. The vaccines of the present invention may also be administered by the rectal route. In such cases the excipients may also include waxes and polymers known in the art for forming rectal suppositories.
The formulations of the present invention may be used for both prophylactic and therapeutic purposes. Accordingly, the present invention provides for a method of treating a mammal susceptible to or suffering from an infectious disease or cancer, or allergy, or auto-immune disease. In a further aspect of the present invention there is provided an adjuvant combination and a vaccine as herein described for use in medicine. Vaccine preparation is generally described in New Trends and .
Developments in Vaccines, edited by Voller et al., University Park Press, Baltimore,
Maryland, U.S.A. 1978.
In an alternative, related embodiment of the present invention the adjuvant of the present invention may further be combined with other adjuvants including Cholera toxin and its B subunit, Monophosphory! Lipid A and its non-toxic derivative 3-de-O- acylated monophosphoryl lipid A (as described in UK patent no. GB 2,220,211), immunologically active saponin fractions e.g. Quil A derived from the bark of the )
South American tree Quillaja Saponaria Molina and derivatives thereof (for example } - USZ1, US Patent No.5,057,53U}, and the oligonucleotide adjuvant system CpG (as ST described in WO 96/02555), especially > TCG TCG TTT TGT CGT TTT GTC GTT* (SEQ ID NO. 1).
The present invention is illustrated by, but not limited to, the following examples.
In the examples below we used whole egg-grown flu virus inactivated with formaldehyde, or TWEEN-ether split virus or NaDOC split egg-grown virus supplemented with Triton X-100. The concentrations of the Tween-80 and Triton X- 100 are shown in the examples.
a. Example 1, Methods used to measure antibody (Ab) responses in sera
ELISA for the measurement of influenza-specific serum Ig Abs:
Maxisorp Nunc immunoplates are coated overnight at 4°C with 50 pl/well of 1 pg/ml
HA of B-propiolactone (BPL) inactivated influenza virus (supplied by SSD GmBH manufacturer, Dresden, Germany) diluted in PBS. Free sites on the plates are blocked (1 hour, 37°C) using saturation buffer: PBS containing 1%BSA, 0.1% polyoxyethylene sorbitan monolaurate (TWEEN 20). Then, serial 2-fold dilutions (in saturation buffer, 50 pl per well) of a reference serum added as a standard curve (serum having a mid-point titer expressed as ELISA Unit/ml, and put in row A ) and serum samples (starting at a 1/100 dilution and put in rows B to H) are incubated for lhr 30mins at 37°C. The plates are then washed (x3) with washing buffer (PBS, 0.1% polyoxyethylene sorbitan monolaurate (TWEEN 20)). Then, biotinylated goat anti- human Ig (Amersham) diluted 1/3000 in saturation buffer are incubated (50 pl/well) for 1hr 30mins, at 37°C. After 3 washings, and subsequent addition of streptavidin- horseradish peroxidase conjugate (Amersham), plates are washed 5 times and incubated for 20 min at room temperature with 50 ul/well of revelation buffer (OPDA
Co 0.4 mg/ml (Sigma) and H,0; 0.03% in 50mM pH 4.5 citrate buffer). Revelation is
To stopped by adding 50 pl/well H;SO,4 2N. Optical densities are read at 492 and 630 nm he by using Biorad 3550 immunoreader. Antibody titre are calculated by the 4 parameter - mathematical method using SoftMaxPro software.
Hemagglutination Inhibition (HAI) activity of Flu-specific serum Abs in mice ) Sera (25 pl) are first treated for 20 minutes at room temperature (RT) with 100 pl borate 0.5M buffer (pH 9) and 125 ul Dade Behring-purchased kaolin. After centrifugation (30 minutes, 3000 RPM or 860 g), 100 pl supernatant (corresponding to a 1/10 dilution of the serum) are taken and incubated for 1 hour at 4°C with 0.5% chicken red blood cells. Supernatant is collected after centrifugation for 10 minutes at 3200 RPM (970 g). Both operations are done for eliminating the natural : hemagglutinating factors contained in the sera. Then, 25 ul treated-sera are diluted in pl PBS (serial 2-fold dilutions starting at 1/20) in 96 well Greiner plates. BPL inactivated whole virus is added (25 pl / well) at a concentration of 4
Hemagglutination Units (i.e. at a dilution which is 4-fold lower than the last one e, » provoking an agglutination of red blood cells) for 30 minutes at RT under agitation.
Chicken red blood cells are then added (25 pl / well) for 1 hour at RT. Plates are finally kept overnight at 4°C before to be read. The HAI titer corresponds to the inverse of the last serum dilution inhibiting the virus-induced hemagglutination.
Example, Effect of TWEENSO and Triton on the intranasal immunogenicity of inactivated whole influenza virus in mice
In the past, the pre-clinical evaluations of alternative influenza vaccines (e.g. adjuvanted parenteral vaccines, DNA-based vaccines or mucosally delivered vaccines) have mainly been performed in naive animals. In general, the promising results obtained from these studies were not confirmed in humans. This was probably due to the fact that the majority of adults have been immunologically “primed” through natural infections before vaccination, unlike the naive animals.
Therefore, the best way to evaluate intranasal influenza vaccines in animal models would be to test their ability to boost pre-established immune responses in nasally primed animals. We assess in the present example the effect of TWEEN-80 and
Triton X-100 on such responses.
The priming was done in female Balb/c mice (8 weeks old) at day 0 by administering with a pipette (under anesthesia) in each nostril 2.5 ug HA of BPL-inactivated --A/Beijing/262/95 influenza virus contained in 10 ul PBS. After 28 days, mice (6 animals/group) were boosted intranasally (under anesthesia) with 20 pl of solution (10 oo ul per nostril, delivered 48 dropiets by pipette) containing 3 pg Hi of BFL= SE inactivated A/Beijing/262/95 influenza virus in either A: PBS; B: TWEENS0 (0.11%) plus Triton X-100 (0.074%) ; or by C: intramuscular injection of 1.5 pg HA of influenza vaccine. Antigens were supplied by SSD GmBH manufacturer (Dresden,
Germany). HAI Ab responses were measured in sera as described in Example 1.
As shown in the Figure 1, when formulated with TWEENS80 and Triton, inactivated influenza virus delivered intranasally-is capable of boosting pre-established systemic
HAI Ab responses as efficiently as the classical parenteral influenza vaccine.
However, the same antigen given intranasally in the absence of TWEENS80 and Triton
Is significantly less immunogenic.
[. 3 wl
Example 3: A comparison of the immunogenicity of an intranasal split influenza vaccine with TWEEN 80 & TRITON X-100 compared to a licensed conventional parenteral vaccine (Fluarix™) in healthy adult subjects.
Formulations used in the study
Two formulations (A,B) of egg-derived split influenza antigens have been evaluated.
A is an intranasal formulation and B is the Fluarix™/ca-Rix® given intramuscularly.
The formulations contain three inactivated split virion antigens prepared from the
WHO recommended strains of the 1998/1999 season.
The device used for intranasal delivery is the Accuspray™ intranasal syringes from
Becton Dickinson. 100ul of the A formulation is sprayed in each nostril.
Composition of the formulations.
The intranasal formulation (A) contains the following inactivated split virions: 1. 30ug HA A/Beijing/262/95 (HIN1) 2. 30ug HA A/Sydney/5/97 (H3N2) 3. 30ug HA of B/Harbin/7/94 and phosphate buffered saline pH 7.4+ 0.1, Tween 80 0.1%, Triton X-100 0.015%, Na deoxycholate 0.0045% and thiomersal below 35ug/ml. ) The volume of one dose is 200ul (100u! sub-doses for each nostril). ) The comparator Fluarix™/a-Rix® is the SmithKline Beecham Biologicals’ commercial inactivated trivalent split influenza vaccine. The dose of 500pl is administered intramuscularly.
This dose contains; 15ug HA of the three strains mentioned above, Tween 80 between 500 and 1000 pg per ml (0.05%-0.1%), Triton X-100 between 50 and 170pg/ml (0.005%-0.017%), sodium deoxycholate maximum 100ug/ml, thiomersal 100ug/mi and phosphate buffered saline pH between 6.8 and 7.5.
EE
Immunogenicity Study
An open, controlled and randomised study evaluated the immunogenicity of an intranasal split influenza vaccine formulated with Tween 80 & Triton X-100 compared to the conventional parenteral vaccine (i.e. Fluarix™). Twenty healthy adult subjects (aged 18-40 years) received one dose of Fluarix™ and ten subjects received one dose of the intranasal influenza vaccine. The intranasal formulation (200ul) contained the following inactivated virions: 30ug of haemagglutinin
A/Beijing/262/95 (HIN1), 30pg of haemagglutinin A/Sydney/5/97 (H3N2), 30ug of haemagglutinin B/Harbin/7/94 with phosphate buffered saline (pH 7.4 + 0.1), Tween 80 (0.1%), Triton X-100 (0.015%), sodium deoxycholate (0.0045%) and thiomersal (<35pg/ml).
There was an eight-day follow-up period for solicited local and general symptoms and both vaccines were well-tolerated regarding safety and reactogenicity. No serious adverse events related to vaccination were reported.
The immunogenicity of the vaccines was examined by assessing the serum ~ haemagglutination inhibition (HI) titres to determine the seroconversion rate (defined _ as the percentage of vaccinees who have at least a 4-fold increase in serum HI titres on day 21 compared to day 0, for each vaccine strain), conversion factor (defined as the fold increase in serum HI Geometric Mean Titres (GMTs) on day 21 compared to day 0, for each vaccine strain) and seroprotection rate (defined as the percentage of ) vaccinees with a serum HI titre 240 after vaccination (for each vaccine strain) that is accepted as indicating protection). Getnietully, an influenza vavuine needs to have > of SE equal to 40% seroconversion rate, > or equal to 70% seroprotection rate and a conversion factor of > or equal to 2.5, for each strain, in order to meet the international regulatory requirements. This applies for adults between 18-60 years; different criteria apply for the elderly.
In addition, the mucosal IgA antibody response was assessed by Enzyme Linked
Immunosorbent Assay (ELISA).
. WO001/21207 PCT/EP00/093 66 ws Ra
HI seropositivity, serconversion and seroprotection rates twenty-one days after one dose of Fluarix™ or the intranasal formulation can be seen in Table 1.
Table 1:
HI seropositivity, seronversion and seroprotection rates at 21 days post dose 1
Seropositivity | Seroprotection | Seroconversion
Group Timing | N n Y% n % n %
A/Beijing | Intranasal vaccine plus Day 0 20 4 20.0 0 0.0
Fluarix™ Day 0 4 21.1 3 15.8
Nt
A/Sydney | Intranasal vaccine plus Day 0 20 13 65.0 3 15.0
Fluarix™ Day 0 14 73.7 1 53
EEE
B/Harbin | Intranasal vaccine plus Day 0 20 10 50.0 7 35.0
Fluarix™ Day 0 17 89.5 11 57.9
EERE EE
Seropositivity (n,%) : number and percentage of subjects with titer = 10
Seroprotection (n,%) : number and percentage of subjects with titer > 40
Seroconversion (n,%) : number and percentage of subjects with at least a 4-fold increase in titres } from day 0 to day 21
In all cases, the conversion factor (fold increase in serum HI GMTs after vaccination) was greater than 2.5, the level required for a successful influenza vaccine.
The percentage of subjects with a two-fold or a four-fold increase in the specific/total mucosal IgA antibody ratio between day 21 and day 0 (1 dose) can be seen in Table 2.
Re 2B | ~
Table 2:
Percentages of subjects with a two-fold or a four-fold increase in the specific/total
IgA ratio between day 21 and day 0 (1 dose). 2 fold increase | 4 fold increase
Group N (%) (%)
A/Beijing Tween & Triton 20 55.0 30.0
Fluarix™ 19 52.6 26.3
A/Sydney Tween & Triton 20 65.0 45.0
Fluarix™ 19 47.4 53
B/Harbin Tween & Triton 20 40.0 30.0
Fluarix™ 19 26.3 53
The immunogenicity results tabulated above show that the intranasal formulation produced similar levels of seropositivity, seroconversion and seroprotection to those produced by the conventional parenteral vaccine (Fluarix™) twenty-one days after one dose. The intranasal formulation produced a better mucosal IgA response after one dose than the conventional parenteral vaccine (Fluarix™).
Claims (23)
1. The use of a combination of a polyoxyethylene sorbitan ester and an octoxynol in the preparation of an adjuvant for application to a mucosal surface of a patient
2. The use according to claim 1, wherein said polyoxyethylene sorbitan ester is polyoxyethylene sorbitan monooleate (TWEENS0™),
3. The use according to claim 1 or claim 2, wherein said octoxynol is t- octylphenoxypolyethoxyethanol (TRITON X-100™™).
4. The use according to any one of claims 1 to 3, further comprising a bile salt or ~ acholic acid derivative.
5. The use of an adjuvant according to any one of claims 1 to 4, together with an antigen, in the manufacture of a vaccine for mucosal administration.
6. The use according to claim 5 wherein said antigen is selected from the group comprising: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1, Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory Syncytial virus, human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Streptococcus, Mycoplasma, Mycobacteria, Haemophilus, Plasmodium or Toxoplasma, stanworth decapeptide; or Tumour associated antigens (TMA), MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH, CEA, PSA, KSA, or PRAME.
7. The use according to claim 6, wherein said antigen is an antigen or antigenic
. preparation from influenza virus.
8. The use according to claim 7, wherein the antigenic preparation is a split ) influenza virus preparation.
9. The use according to claim 7 or claim 8, for the manufacture of a vaccine for prophylaxis against influenza.
10. The use according to any one of claims 5 to 9, for the manufacture of a vaccine for use in medicine.
11. A method of producing a vaccine which method comprises admixing (a) a polyoxyethylene sorbitan ester, (b) an octoxynol and (c) an antigen, and providing the vaccine in the form of a vaccine dose for mucosal administration.
12. The method according to claim 11, wherein the vaccine is provided in an intranasal aerosol or spray device.
13. A spray or aerosol device, more particularly a bi-dose device, filled with a
‘WO olnno7 PCT~M366 vaccine comprising a polyoxyethylene sorbitan ester, an octoxynol and an antigen
14. The spray or aerosol device according to claim 13, wherein the antigen is an influenza antigen or antigenic preparation.
15. The spray or aerosol device according to claim 14, wherein the antigenic . preparation is a split influenza virus preparation.
16. A vaccine composition comprising a polyoxyethylene sorbitan ester, an octoxynol and an antigen, for use in treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, wherein said vaccine. composition is administed to the mucosa of the mammal.
17. The use of claim 16, wherein the vaccine is administered intranasally.
18. The use of claim 16 or 17, wherein the vaccine is an influenza virus vaccine comprising an influenza antigen or antigenic preparation, such as a split influenza virus preparation.
19. Use according to claim 1, substantially as herein described and exemplified and/ or described with reference to the accompanying figure.
20. A method of producing a vaccine according to claim 11, substantially as herein described and exemplified and/or described with reference to the accompanying figure.
21. A spray or aerosol device according to claim 13, substantially as herein described and exemplified and/or described 'with reference to the accompanying figure.
22. A vaccine composition according to claim 16, substantially as herein described and exemplified and 1 or described with reference to the accompanying figure.
23 AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9922703.5A GB9922703D0 (en) | 1999-09-24 | 1999-09-24 | Vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200202270B true ZA200202270B (en) | 2003-02-12 |
Family
ID=10861595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200202270A ZA200202270B (en) | 1999-09-24 | 2002-03-20 | Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines. |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB9922703D0 (en) |
ZA (1) | ZA200202270B (en) |
-
1999
- 1999-09-24 GB GBGB9922703.5A patent/GB9922703D0/en not_active Ceased
-
2002
- 2002-03-20 ZA ZA200202270A patent/ZA200202270B/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB9922703D0 (en) | 1999-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU765824B2 (en) | Vaccines | |
AU766635B2 (en) | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant | |
AU746163B2 (en) | Adjuvant compositions | |
ES2397714T3 (en) | Vaccine comprising an oil-in-water emulsion adjuvant | |
AU2001286168B2 (en) | Oral solid dose vaccine | |
ES2293923T3 (en) | INTRANASAL VACCINE AGAINST THE INFLUENZA VIRUS. | |
US20020058047A1 (en) | Vaccines | |
AU2001286168A1 (en) | Oral solid dose vaccine | |
KR20190025822A (en) | Pegylated liposomes and their uses | |
EP1528914B1 (en) | Antigenic compositions | |
WO2004016281A1 (en) | Intradermal influenza vaccine compositions containing an adp-ribosylating factor | |
ZA200202270B (en) | Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines. | |
ZA200202268B (en) | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one non-ionic surfactant. | |
CZ20003732A3 (en) | Auxiliary preparation | |
MXPA00009887A (en) | Adjuvant compositions |